ABSTRACT
INTRODUCTION

36
Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis 37 transmembrane conductance regulator (CFTR) protein that resides at the apical surface of many 38 epithelial cell types. CFTR defects result in abnormal chloride and bicarbonate transport, increasing 39 mucus viscosity in the pancreas, paranasal sinuses, digestive tract, and most notably, the lower airways.
40
Viscous mucus, due to its impaired clearance and nutrient bioavailability, in turn becomes chronically 41 colonized by pathogenic bacteria that are the leading cause of mortality among the CF population (1) . 
60
xylosoxidans during chronic infection of the CF lung.
61
Relative to canonical CF pathogens, comparatively little is known about the molecular 62 mechanisms of biofilm formation and maintenance in A. xylosoxidans. This is due, in part, to the paucity 63 of genetic tools available for manipulation of its genome. Therefore, the objectives of this study were two-64 fold: First, we sought to develop a tractable system to genetically manipulate A. xylosoxidans. Using this 65 system, our second objective was to take a transposon mutagenesis approach to study the molecular 66 basis of A. xylosoxidans biofilm formation. In doing so, we identified several gene products essential for 67 biofilm development. We chose to further characterize a gene identified most frequently in our screen 68 (echA) encoding a putative enoyl-CoA hydratase that, when disrupted, leads to a decrease in biofilm 69 accumulation and increased susceptibility to multiple classes of antibiotics.
71
RESULTS
72
Identification of biofilm-defective mutants via transposon mutagenesis. To identify genetic 73 determinants of biofilm formation in A. xylosoxidans, we generated a mutant library of strain MN001 74 using random transposon mutagenesis employing the mini-mariner transposable element (21) . From this 75 library, 15,000 mutants were screened for altered biofilm formation using an established crystal violet 76 (CV) / microtiter dish assay (22). After an initial round of screening, 134 putative biofilm-defective 77 mutants were identified, and putative hits were then re-tested (n=4) to verify mutant phenotypes. After 78 secondary screening and eliminating mutants with general growth defects, 31 transposon mutants were 79 confirmed to be defective in biofilm accumulation (Fig. 1, Table 1 ).
80
To identify DNA sequences (~200-400 bp) flanking transposon insertion junctions, mutants were 81 screened by arbitrarily-primed PCR. Insertions were mapped to loci predicted to encode various classes 82 of gene products, including membrane proteins, glycosyltransferases, flagella, transcriptional regulators, 83 in addition to several proteins with no assigned function (Table 1) . Arbitrary PCR of three transposon 84 insertion loci generated sequences with no homology to published gene sequences, and we were unable 85 to obtain transposon-flanking sequences for five additional mutants. Of note, a putative enoyl-CoA 86 hydratase, an exonuclease, and a propionate hydroxylase were each hit multiple times. We took interest 87 in the gene encoding a putative enoyl-CoA hydratase (Axylo_0405) given the importance of homologous 88 5 proteins in fatty acid signal biosynthesis and biofilm development among diverse bacterial species (23-89 29). We named this gene echA (for enoyl-CoA hydratase A) and sought to characterize its effects on A.
90
xylosoxidans biofilm physiology in greater detail.
91
Generation and complementation of an echA mutant. Genetic tractability has been challenging for A.
92
xylosoxidans due its inherent resistance to multiple classes of antibiotics and inducible efflux system as a 93 second line of defense (12,13,15). We therefore sought to develop a robust genetic system for the 94 generation and complementation of marker-free deletion mutants that would facilitate further study of the 95 genetic basis of biofilm formation. Given that tetracycline resistance was an effective marker to generate 96 the transposon mutant library, the tetracycline resistance cassette from pEX18tc (30) was PCR amplified 97 and ligated into the mobilizable suicide vector pSMV8 (31) generating pBMB1 (empty vector) and pBMB2
98
(echA deletion construct; Figure S1 ). Attempts to construct a complementation vector using broad host-99 range cloning plasmids were unsuccessful. We therefore introduced echA into pBMB3 (pBBR1MCS- (Table 1) were a result of mutations in 105 echA, we re-assessed biofilm formation by the markerless ΔechA mutant using the CV assay described 106 above. As before, ΔechA exhibited a significant decrease in biofilm biomass accumulation relative to the 107 wildtype (p=0.002) after 72h (Fig. 2) . Complementation with pBMB4 restored the wildtype phenotype 108 (p=0.023), confirming a role of echA and its gene product in A. xylosoxidans biofilm development. to test whether the observed biofilm impairment phenotype in A. xylosoxidans was also mediated by a 114 DSF-like signaling mechanism, we exogenously added synthetic cis-DA (310nM) (35) to the ΔechA 6 mutant during biofilm development. Despite having no effect on the WT strain (not shown), addition of 116 cis-DA to ΔechA resulted in a significant restoration of biofilm biomass relative to the untreated control 117 (p=0.024) (Fig. 2) . These data suggest that biofilm formation in MN001 is directly mediated by a DSF-like 118 metabolite generated by an enoyl-CoA hydratase. other genes identified in our screen (see Table 1 ) will undoubtedly generate new insights into the many 181 aspects of Achromobacter biofilm physiology that remain uncharacterized. 
METHODS
216
Bacterial strains, plasmids, and growth conditions. Bacterial strains used are listed in Table S1 . A.
217
xylosoxidans MN001 (54) and Escherichia coli were grown in lysogeny broth (LB) at 37°C unless 218 otherwise specified. When necessary, growth media were supplemented with gentamicin at 20 μg/ml (E.
219
coli) or 100 μg/ml (A. xlyosoxidans), ampicillin at 100 μg/ml (E. coli) or 300 μg/ml (A. xylosoxidans), 220 carbenicillin (300 μg/ml), tetracycline (300 μg/ml), or chloramphenicol (30 μg/ml). E. coli strain β2155 was 221 supplemented with 60 mM diaminopimelic acid (DAP). Table   254 S2)(56). The second round included nested primers (pair 2) unique to the transposon and 5' end of the 255 arbitrary primer for amplification of PCR products obtained in the first round. PCR products were 256 sequenced at the University of Minnesota Genomics Center (UMGC) and were mapped to the A.
257
xylosoxidans MN001 genome (Accession#PRJNA288995).
258
Construction and complementation of an echA deletion mutant. To generate a deletion vector 259 compatible with A. xylosoxidans, pSMV8 (57) was first digested using ApaI. A tetracycline resistance 260 cassette was then amplified from pEX18tc (31) using primer pair 3 (Table S2 ) and digested with ApaI.
261
Vector and insert (1:3 ratio) were then ligated using T4 ligase, transformed into E. coli UQ950 and 262 selected for on LB agar containing tetracycline (15 μg/mL). Colonies were screened using primers M13F
263
and TetR (pair 4) to confirm insertion orientation. One plasmid, pBMB1, was selected for further use.
264
To generate an in-frame, unmarked deletion of Achromo51_0405 (echA), ~1kb sequences 265 flanking echA were PCR amplified using primer pairs 5 and 6 (Table S2 ). These flanking regions were 266 combined and cloned into pBMB1 digested with SpeI and XhoI using Gibson assembly, resulting in 267 pBMB2 ( Figure S1 ). This plasmid was then chemically transformed into UQ950, and positive ligations 268 were screened by PCR. pBMB2 was then transformed into E. coli strain WM3064 and mobilized into A.
269
xylosoxidans MN001 by conjugation. Recombinants were selected for on LB-tetracycline agar and 270 double recombinants were selected for on LB agar containing 6% sucrose.
271
Complementation was achieved via exogenous expression of echA (Ax_0405) from pBBR1MCS-272 5 (57). To do so, an alcohol inducible promoter, alcA (32) was first amplified from pGGA008 using 273 primers alcA_F and alcA_R (Table S2) 
